Pharma Strategy Blog

Commentary on Pharma & Biotech Oncology / Hematology New Product Development

After spending the long weekend listening and learning about literally 100's of cancer studies and hearing about the tragic Air France flight that resulted in the loss of over 200 lives, I was reminded of how fragile and short life can sometimes be, how pure chance can change the course of things forever.

For me, this afternoon is quiet time for reflection and restoration of one's karma after the hurly burly of life with a long walk in a local park.  Getting out for fresh air on a glorious day can't be beat!

IMG_1301

The Pharma Strategy Blog will be back tomorrow refreshed and energised, with a series of updates based on news from ASCO in a variety of pathways and tumour types.

For now, adios!

Reblog this post [with Zemanta]

2 Responses to “Reflections from a cancer conference”

  1. Dom

    Nice post! What happened to PI-103? You didn’t mention that one.

  2. MaverickNY

    You mean in the PI3-Kinase blog post?
    Well, as far as I can tell, PI-103 was owned by Piramar, a private biotech company in the UK. It appears to have been purchased by Roche in April last year see http://pharmtech.findpharma.com/pharmtech/Company+and+People+Notes/Company-and-People-Notes-Roche-to-Acquire-Piramed-/ArticleStandard/Article/detail/510269?ref=25
    Not sure what happened to it in Roche’s pipeline though as it does not seem to appear here
    http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm
    Only the Genentech one is mentioned, which is probably GDC-0941

Comments are closed.

error:
error: Content is protected !!